Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,480 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study.
Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niiro H, Tamura N, Banno S, Yoshifuji H, Sakata Y, Kawakami A, Atsumi T, Furuta S, Kohsaka H, Suzuki K, Hara R, Maejima Y, Tsukamoto H, Takasaki Y, Yamashita K, Okada N, Yamakido S, Takei S, Yokota S, Nishimoto N. Nakaoka Y, et al. Among authors: yamashita k. Rheumatology (Oxford). 2020 Sep 1;59(9):2427-2434. doi: 10.1093/rheumatology/kez630. Rheumatology (Oxford). 2020. PMID: 31951279 Free PMC article. Clinical Trial.
Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: Three approaches with a cohort simulation and real-world data.
Kuwana M, Tamura N, Yasuda S, Fujio K, Shoji A, Yamaguchi H, Iwasaki K, Makishima M, Kawata Y, Yamashita K, Igarashi A. Kuwana M, et al. Among authors: yamashita k. Mod Rheumatol. 2023 Mar 2;33(2):302-311. doi: 10.1093/mr/roac038. Mod Rheumatol. 2023. PMID: 35445720
Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database.
Harigai M, Fujii T, Sakai R, Igarashi A, Shoji A, Yamaguchi H, Iwasaki K, Makishima M, Yoshida A, Okada N, Yamashita K, Kawahito Y. Harigai M, et al. Among authors: yamashita k. Mod Rheumatol. 2024 Feb 26;34(2):287-296. doi: 10.1093/mr/road031. Mod Rheumatol. 2024. PMID: 37039670
5,480 results